Protocol Details

Environment and Alcohol: A Pilot Study

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

002341-DA

Sponsoring Institute

National Institute on Drug Abuse (NIDA)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 21 Years
Max Age: 100 Years

Referral Letter Required

No

Population Exclusion(s)

Pregnant Women;
Children;
Non-English Speaking

Keywords

Alcohol Use Disorder

Recruitment Keyword(s)

None

Condition(s)

Alcohol Use Disorder

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Behavioral: Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption

Supporting Site

National Institute on Drug Abuse

Background:

Alcohol use disorder (AUD) is a chronic disease that causes more than 140,000 US deaths each year. AUD treatment often includes therapy and medication. Some people with AUD may also benefit from behavioral and lifestyle changes.

Objective:

To evaluate the effects of different activities and environments on drinking behaviors and mental health in people with AUD.

Eligibility:

People aged 21 years and older with AUD.

Design:

Participants will have up to 10 study visits in Baltimore.

Participants will have a baseline visit. They will have a physical exam with blood and urine tests. They will have a breath test for alcohol and a test that measures body composition. They will answer questions about their alcohol and substance use; mental and physical health; mood and anxiety; and sleep quality.

Participants will download an app called MetricWire. The app will send 3 sets of questions to be answered at different times throughout the day.

The study visits will include 2 stages:

(1) Active stage. On these visits, participants will use a virtual reality system called the Meta Quest Pro (MQP) as they choose. Then they may choose among video games, puzzles, books, crafts, and other activities.. These sessions will last for 3 hours.

(2) Passive stage. On these visits, participants will watch videos selected by the research team. These sessions will last for 3 hours.

On the last visit of each stage, participants will sit in a room that looks like a bar. They will answer questions about their cravings, their urge to drink, and how many drinks they would buy. Participants will be served 1 drink containing alcohol. They will be asked about their cravings and subjective effects of alcohol after drinking it.

Eligibility

INCLUSION CRITERIA:

To meet eligibility for this study, participants must meet all the following criteria:

1. At least 21 years old

2. Owns a cellular device ("smart phone") and is willing to download the EMA application and use it to answer the study questionnaires

3. Diagnosis of alcohol use disorder (minimum of 2 DSM-5 criteria on a valid diagnostic tool, e.g., Mini-International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM Disorders (SCID))

4. Self-reported drinking, according to alcohol Timeline Follow-Back (TLFB), of > 7 drinks per week for females or > 14 drinks per week for males, on average, during the 28-day period prior to screening + at least four days with > 3 drinks for females or > 4 drinks for males during the 28-day period prior to screening

5. Most recent Clinical Institute Withdrawal Assessment for Alcohol - revised (CIWA-Ar) score < 10

6. If a female of childbearing potential: not pregnant or breastfeeding, no intention to become pregnant during the study duration, and agrees to use a highly effective contraception method to prevent pregnancy for the entire study duration. Highly effective contraception methods will be determined by the MAI or designee.

EXCLUSION CRITERIA:

Any individual who meets any of the following criteria will be excluded from this study:

1. Current use of FDA-approved pharmacotherapy for AUD (or of a medication intended as an off-label use to treat AUD as determined by the MAI), or currently seeking treatment for AUD

2. Medical and/or mental health conditions that are clinically unstable and would therefore compromise the safety and/or scientific integrity of the study, as determined by the MAI or study team respectively.

3. Known history of clinically significant cybersickness.

4. Any other reason or clinical condition that the Investigators judge would interfere with study participation and/or be unsafe for a participant

5. Unable to speak, read, write, and understand English

Justification: Many of the assessments have only been validated in English, and therefore, a non-English translation would jeopardize the scientific integrity of the study.


Citations:

Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8. PMID: 27475769; PMCID: PMC6135092.

Nicastri CM, McFeeley BM, Simon SS, Ledreux A, H(SqrRoot)(Bullet)kansson K, Granholm AC, Mohammed AH, Daffner KR. BDNF mediates improvement in cognitive performance after computerized cognitive training in healthy older adults. Alzheimers Dement (N Y). 2022 Aug 30;8(1):e12337. doi: 10.1002/trc2.12337. PMID: 36089933; PMCID: PMC9428279.

Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006 Sep;7(9):697-709. doi: 10.1038/nrn1970. PMID: 16924259.

Edwards S, Kenna GA, Swift RM, Leggio L. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des. 2011;17(14):1323-32. doi: 10.2174/138161211796150765. PMID: 21524263.

Contacts:

Principal Investigator

Referral Contact

For more information:

Lorenzo Leggio, M.D.
National Institute on Drug Abuse (NIDA)
NIH BIOMEDICAL RESEARCH CENTER BG RM 04A515
251 BAYVIEW BLVD.
BALTIMORE MD 21224
(240) 478-1503
lorenzo.leggio@nih.gov
Ryan E. Tyler
National Institute on Drug Abuse (NIDA)

(240) 789-0347
ryan.tyler@nih.gov
Lorenzo Leggio, M.D.
NIH BIOMEDICAL RESEARCH CENTER BG RM 04A515
251 BAYVIEW BLVD.
BALTIMORE MD 21224
(443) 740-2801
lorenzo.leggio@nih.gov

Clinical Trials Number:

NCT06860607
Was this page helpful?